Stock News & Analysis

Join us as we dissect Lululemon's stock performance and explore whether it can reclaim its former glory in the competitive athleisure market. Will it be a market beater or a missed opportunity?

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Both of these electric air taxi pioneers have sold off hard recently, creating a potential entry point for patient investors.

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

One fund just walked away from a rising offshore driller—here’s what long-term investors should make of the move.

Semtech’s turnaround is gaining momentum—and one fund just made a sizable bet on what comes next.

Investing in artificial intelligence infrastructure is a sound strategy.

GEO’s latest quarter shows a company pulling in record contracts while wrestling with litigation and cooling earnings guidance—here’s what investors need to know.

IonQ has spent the last year acquiring several businesses.

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

One semiconductor supplier’s surge in institutional demand is revealing where smart money expects the next leg of tech growth to unfold.

A fast-growing niche segment may be the real reason this small-cap consumer products stock is drawing new institutional attention.

Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position.

One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.

One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds.

These three low-cost funds offer exposure to international dividends, U.S. technology, and small-cap value -- the building blocks of a diversified portfolio.

Explosive growth has fueled Hyperliquid's rapid ascent over the past 12 months.

This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline.

Nvidia's growth story is far from finished.